Literature DB >> 26878343

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.

Nicholas F Pelz1, Zhiguo Bian1, Bin Zhao1, Subrata Shaw1, James C Tarr1, Johannes Belmar1, Claire Gregg1, DeMarco V Camper1, Craig M Goodwin1, Allison L Arnold1, John L Sensintaffar1, Anders Friberg1, Olivia W Rossanese1, Taekyu Lee1, Edward T Olejniczak1, Stephen W Fesik1.   

Abstract

Myeloid cell leukemia-1 (Mcl-1) is a member of the Bcl-2 family of proteins responsible for the regulation of programmed cell death. Amplification of Mcl-1 is a common genetic aberration in human cancer whose overexpression contributes to the evasion of apoptosis and is one of the major resistance mechanisms for many chemotherapies. Mcl-1 mediates its effects primarily through interactions with pro-apoptotic BH3 containing proteins that achieve high affinity for the target by utilizing four hydrophobic pockets in its binding groove. Here we describe the discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design. These novel inhibitors exhibit low nanomolar binding affinities to Mcl-1 and >500-fold selectivity over Bcl-xL. X-ray structures of lead Mcl-1 inhibitors when complexed to Mcl-1 provided detailed information on how these small-molecules bind to the target and were used extensively to guide compound optimization.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26878343      PMCID: PMC5565212          DOI: 10.1021/acs.jmedchem.5b01660

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Cell death: critical control points.

Authors:  Nika N Danial; Stanley J Korsmeyer
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 3.  Profiling drug-like properties in discovery research.

Authors:  Li Di; Edward H Kerns
Journal:  Curr Opin Chem Biol       Date:  2003-06       Impact factor: 8.822

4.  The CCP4 suite: programs for protein crystallography.

Authors: 
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-09-01

Review 5.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

6.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

Review 7.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

Review 8.  Targeting apoptosis pathways in cancer therapy.

Authors:  Irene M Ghobrial; Thomas E Witzig; Alex A Adjei
Journal:  CA Cancer J Clin       Date:  2005 May-Jun       Impact factor: 508.702

9.  Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.

Authors:  Zaneta Nikolovska-Coleska; Renxiao Wang; Xueliang Fang; Hongguang Pan; York Tomita; Peng Li; Peter P Roller; Krzysztof Krajewski; Naoyuki G Saito; Jeanne A Stuckey; Shaomeng Wang
Journal:  Anal Biochem       Date:  2004-09-15       Impact factor: 3.365

Review 10.  Structural biology of the Bcl-2 family of proteins.

Authors:  Andrew M Petros; Edward T Olejniczak; Stephen W Fesik
Journal:  Biochim Biophys Acta       Date:  2004-03-01
View more
  24 in total

1.  Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.

Authors:  Jeffrey W Johannes; Stephanie Bates; Carl Beigie; Matthew A Belmonte; John Breen; Shenggen Cao; Paolo A Centrella; Matthew A Clark; John W Cuozzo; Christoph E Dumelin; Andrew D Ferguson; Sevan Habeshian; David Hargreaves; Camil Joubran; Steven Kazmirski; Anthony D Keefe; Michelle L Lamb; Haiye Lan; Yunxia Li; Hao Ma; Scott Mlynarski; Martin J Packer; Philip B Rawlins; Daniel W Robbins; Haidong Shen; Eric A Sigel; Holly H Soutter; Nancy Su; Dawn M Troast; Haiyun Wang; Kate F Wickson; Chengyan Wu; Ying Zhang; Qiuying Zhao; Xiaolan Zheng; Alexander W Hird
Journal:  ACS Med Chem Lett       Date:  2016-12-27       Impact factor: 4.345

2.  Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.

Authors:  Taekyu Lee; Zhiguo Bian; Bin Zhao; Leah J Hogdal; John L Sensintaffar; Craig M Goodwin; Johannes Belmar; Subrata Shaw; James C Tarr; Nagarathanam Veerasamy; Shannon M Matulis; Brian Koss; Melissa A Fischer; Allison L Arnold; DeMarco V Camper; Carrie F Browning; Olivia W Rossanese; Amit Budhraja; Joseph Opferman; Lawrence H Boise; Michael R Savona; Anthony Letai; Edward T Olejniczak; Stephen W Fesik
Journal:  FEBS Lett       Date:  2016-12-19       Impact factor: 4.124

Review 3.  From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors.

Authors:  Avi Ashkenazi; Wayne J Fairbrother; Joel D Leverson; Andrew J Souers
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

4.  Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.

Authors:  Brandon Drennen; Christopher C Goodis; Nathan Bowen; Wenbo Yu; Gregory Vickers; Paul T Wilder; Alexander D MacKerell; Steven Fletcher
Journal:  RSC Med Chem       Date:  2022-06-03

5.  Selective Covalent Targeting of Anti-Apoptotic BFL-1 by Cysteine-Reactive Stapled Peptide Inhibitors.

Authors:  Annissa J Huhn; Rachel M Guerra; Edward P Harvey; Gregory H Bird; Loren D Walensky
Journal:  Cell Chem Biol       Date:  2016-09-08       Impact factor: 8.116

6.  Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins.

Authors:  Karson J Kump; Lei Miao; Ahmed S A Mady; Nurul H Ansari; Uttar K Shrestha; Yuting Yang; Mohan Pal; Chenzhong Liao; Andrej Perdih; Fardokht A Abulwerdi; Krishnapriya Chinnaswamy; Jennifer L Meagher; Jacob M Carlson; May Khanna; Jeanne A Stuckey; Zaneta Nikolovska-Coleska
Journal:  J Med Chem       Date:  2020-02-14       Impact factor: 7.446

7.  Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells.

Authors:  Jingshan Tong; Peng Wang; Shuai Tan; Dongshi Chen; Zaneta Nikolovska-Coleska; Fangdong Zou; Jian Yu; Lin Zhang
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 13.312

8.  Structure property relationships of N-acylsulfonamides and related bioisosteres.

Authors:  Karol R Francisco; Carmine Varricchio; Thomas J Paniak; Marisa C Kozlowski; Andrea Brancale; Carlo Ballatore
Journal:  Eur J Med Chem       Date:  2021-03-28       Impact factor: 7.088

Review 9.  Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.

Authors:  Lindsey M Ludwig; Michele L Nassin; Abbas Hadji; James L LaBelle
Journal:  Front Pediatr       Date:  2016-12-21       Impact factor: 3.418

10.  Synthesis, Fungicidal Activity, and Structure Activity Relationship of β-Acylaminocycloalkylsulfonamides against Botrytis cinerea.

Authors:  Chun-Hui Liu; Xiao-Yuan Chen; Pei-Wen Qin; Zhi-Qiu Qi; Ming-Shan Ji; Xing-Yu Liu; P Vijaya Babu; Xing-Hai Li; Zi-Ning Cui
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.